Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Sihuan Pharma Files IND for New Anti-Hypertensive Drug

publication date: Mar 12, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Sihuan Pharmaceutical announced its application to begin clinical trials of a new treatment for hypertension was accepted by the SFDA. The company developed Tylerdipine Hydrochloride, a calcium channel blocker, in its own facilities. Sihuan hopes to obtain approval to begin the China trials by the end of 2013, and the company will also seek to run tests of the product in the US. More details....

Stock Symbol: (HK: 0460)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners